KLRC1 and chronic myelogenous leukemia, BCR-ABL1 positive: Reduction of NKG2A+ NK cells by dasatinib, not by imatinib or nilotinib, enhanced overall NK cytotoxicity, which was significantly associated with the effectiveness of treatment responses in CML.